YOU WONT BELIEVE: Revolution medicines - What They Never Told You

Pancreatic Cancer Pill Daraxonrasib Gets FDA Breakthrough Status for Untreated Metastatic Disease When Paired with Standard Chemotherapy

The FDA gave daraxonrasib breakthrough status with gemcitabine and nab-paclitaxel for untreated metastatic pancreatic cancer. The combination is not yet approved.

Medical Daily · Sep 17

Some Pancreatic Cancer Families Hit Insurance Delays After Rasonque Approval Closed the Drug's Free Early Access Program

FDA approval of the pancreatic cancer pill Rasonque closed its free early access program before some insurers were ready to cover it.

Medical Daily · Sep 16

Revolution Medicines Got Its Breakthrough—What Moves It Next?

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

MarketBeat · Sep 4

A pill that doubles survival: Revolution's FDA-approved drug gives pancreatic cancer patients a fighting chance

The US FDA has approved Revolution Medicines' pancreatic cancer drug Rasonque. This once-daily pill doubles survival for patients with advanced metastatic pancreatic cancer. Rasonque blocks the RAS protein, which drives tumor growth in many pancreatic cancers. Doctors hail this development as a significant breakthrough in cancer treatment. The drug is…

The Economic Times · Aug 27

FDA approves new drug Rasonque to treat advanced pancreatic cancer

The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease. A large trial found the once-daily pill doubled survival rates, offering fresh hope for people who have exhausted other treatments.

France 24 · Aug 26

Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet

Dr. Danish Nagda, a shareholder in the developer, told Fortune it was "incredibly exciting ... maybe half a decade away from the post-cancer era."

Fortune · Aug 26

New hope for pancreatic cancer patients after FDA approves drug shown to improve survival

Pancreatic cancer is among the deadliest forms, largely because detection is difficult before malignancy spreads to other organs

The Independent UK · Aug 26

FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer

The Independent UK · Aug 26

FDA Accepts Review of a Pancreatic Cancer Pill Already Reaching Patients Through an Expanded Access Program

The FDA accepted the daraxonrasib application in July, and more than 2,000 patients are already receiving the drug without approval.

Medical Daily · Aug 19

A New Pancreatic Cancer Drug Is Reaching Patients Before Approval and the Testing Rules Are Not What Many Assume

Daraxonrasib is reaching pancreatic cancer patients through expanded access, and the pivotal trial enrolled them regardless of RAS mutation status.

Medical Daily · Aug 11